Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-14T07:00:43.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries

Published online by Cambridge University Press:  26 November 2001

J. M. BAYAS ,
A. GONZÁLEZ ,
A. VILELLA ,
M. SAN-MARTÍN ,
M. J. BERTRAN  and
C. ADELL
J. M. BAYAS
Affiliation:
Adult Vaccination Centre, UASP IOiBAPS Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
A. GONZÁLEZ
Affiliation:
Medical Department, Aventis Pasteur MSD, Madrid, Spain
A. VILELLA
Affiliation:
Adult Vaccination Centre, UASP IOiBAPS Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
M. SAN-MARTÍN
Affiliation:
Medical Department, Aventis Pasteur MSD, Madrid, Spain
M. J. BERTRAN
Affiliation:
Adult Vaccination Centre, UASP IOiBAPS Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
C. ADELL
Affiliation:
Adult Vaccination Centre, UASP IOiBAPS Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Our objectives were to assess the prevalence of anti-hepatitis A (HAV) antibodies in Spanish travellers to developing countries and to carry out a cost analysis to allow the comparison of two vaccination strategies. Adult subjects were selected from among travellers to developing countries. Information was obtained on age, sex, destination, previous vaccination against HAV and having received immunoglobulin. Blood specimens were obtained for anti-HAV antibody determination. A total of 485 travellers were studied. The prevalence of anti-HAV antibody was 30·5% (95% CI 26–35). Antibody prevalence was inversely correlated with age: 9·8% in 18–25 years of age, rising to 75·4% in those 41–55 years of age. Cost analysis determined that the critical value of prevalence for vaccination with HAV vaccine was 37·5%. It was concluded that the youngest Spanish travellers lack anti-HAV antibodies. Vaccination without screening in those [les ] 35 years of age and screening before vaccination for those > 35 years, are the preferred alternatives.

Type
Research Article
Information
Epidemiology & Infection , Volume 127 , Issue 2 , October 2001 , pp. 347 - 351
Copyright
2001 Cambridge University Press